Format

Send to

Choose Destination
Indian Dermatol Online J. 2013 Jan;4(1):54-7. doi: 10.4103/2229-5178.105488.

Topical rapamycin (sirolimus) for facial angiofibromas.

Author information

1
Department of Skin & VD, Mahatma Gandhi Institute of Medical Sciences and Kasturba Hospital, Sewagram, Wardha, Maharashtra, India.

Abstract

Rapamycin (sirolimus) is a fungal fermentation product that inhibits the proper functioning of a serine/threonine protein kinase in mammalian cells eponymously named mammalian target of rapamycin, or mTOR. Rapamycin is a novel class of anticancer and immunosuppressant drugs targeting the proteins at molecular level. Rapamycin (sirolimus) is routinely incorporated in drug-eluting stents used for cardiac angioplasty. In recent years, rapamycin was found to be efficacious in managing the symptom complex of tuberous sclerosis, i.e. renal angiomyolipoma, giant cell astrocytoma and pulmonary lymphangiomyomatosis. Various investigators have also proved that topically applied rapamycin causes regression of facial angiofibromas, giving better cosmetic results.

KEYWORDS:

Facial angiofibromas; Mechanism of action; Rapamycin; Tuberous sclerosis

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center